EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aprea Therapeutics's enterprise value is $-1.09 Mil.
Aprea Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.46 Mil. Therefore, Aprea Therapeutics's EV-to-EBITDA for today is 0.07.
The historical rank and industry rank for Aprea Therapeutics's EV-to-EBITDA or its related term are showing as below:
APRE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.6 Med: 0 Max: 100.53
Current: 0.07
During the past 7 years, the highest EV-to-EBITDA of Aprea Therapeutics was 100.53. The lowest was -11.60. And the median was 0.00.
APRE's EV-to-EBITDA is ranked better than 93.8% of 468
companies
in the Biotechnology industry
Industry Median: 9.155
vs APRE: 0.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Aprea Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Aprea Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aprea Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Aprea Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's EV-to-EBITDA falls into.
Aprea Therapeutics's current Enterprise Value is $-1.09 Mil.
Aprea Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aprea Therapeutics's PE Ratio for today is calculated as:
Aprea Therapeutics's share price for today is $5.10.
Aprea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Aprea Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aprea Therapeutics (Aprea Therapeutics) Business Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APRE has been successfully added to your 